이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

국소 방광암에 대한 Erdafitinib 방광내 전달 시스템 연구

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

비근육 침습성 또는 근육 침습성 방광암 및 선별된 FGFR 돌연변이 또는 융합이 있는 참가자를 대상으로 한 Erdafitinib 방광내 전달 시스템(TAR-210)의 1상 연구

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D[s]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).

연구 개요

상태

모집하지 않고 적극적으로

상세 설명

Bladder cancer is one of the most common malignancy worldwide, and non-muscle invasive (NMIBC) requires intensive regimens of frequent monitoring and local resection (transurethral resection of bladder [TURBT]). This study enrolls participants with non-muscle invasive or muscle invasive bladder cancer with activating fibroblast growth factor receptor (FGFR) mutations or fusions. Erdafitinib is a pan-FGFR inhibitor with demonstrated clinical activity when administered orally in patients with solid tumors, including bladder cancer, with FGFR genetic alterations. The Erdafitinib intravesical delivery system is designed to provide release of Erdafitinib in the bladder to treat localized bladder cancer, while reducing systemic toxicities. The study consists of a screening phase, a treatment phase, and a follow-up phase. Total duration of the study is approximately up to 7 years 4 months.

연구 유형

중재적

등록 (실제)

235

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Nijmegen, 네덜란드, 6525 GA
        • Radboud Umcn
      • Utrecht, 네덜란드, 3584 CX
        • UMC Utrecht
      • Goyang-si, 대한민국, 10408
        • National Cancer Center
      • Gwangju, 대한민국, 61469
        • Chonnam National University Hospital
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, 대한민국, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
      • Dresden, 독일, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Duisburg, 독일, 47169
        • Urologicum Duisburg
      • Frankfurt am Main, 독일, 60590
        • Universitatsklinikum Frankfurt
      • Herne, 독일, 44625
        • Marien hospital Herne
      • Mettmann, 독일, 40822
        • Urologie Neandertal Praxis Mettmann
      • Münster, 독일, 48149
        • Universitatsklinikum Munster
      • Ulm, 독일, 89081
        • Universitaetsklinikum Ulm
    • Alabama
      • Birmingham, Alabama, 미국, 35294
        • University of Alabama at Birmingham - The Kirklin Clinic
    • California
      • Los Angeles, California, 미국, 90033
        • University of Southern California
    • Colorado
      • Lone Tree, Colorado, 미국, 80124
        • Urology Associates of Denver
    • Florida
      • Hialeah, Florida, 미국, 33016
        • Urological Research Network
      • Largo, Florida, 미국, 33771
        • Advanced Urology Institute
      • Orlando, Florida, 미국, 32804
        • Advent Health Orlando
      • Oxford, Florida, 미국, 34484
        • Advanced Urology Institute 1
      • Tampa, Florida, 미국, 33612
        • H Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago Ridge, Illinois, 미국, 60415
        • Associated Urological Specialists
    • Indiana
      • Greenwood, Indiana, 미국, 46143
        • Urology of Indiana
      • Merrillville, Indiana, 미국, 46410
        • Urologic Specialists of Northwest Indiana
    • Kentucky
      • Lexington, Kentucky, 미국, 40506
        • University of Kentucky
    • Louisiana
      • Lafayette, Louisiana, 미국, 70508
        • Southern Urology LLC
    • Massachusetts
      • Plymouth, Massachusetts, 미국, 02360
        • Greater Boston Urology
    • Missouri
      • St Louis, Missouri, 미국, 63141
        • Specialty Clinical Research of St Louis
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • Hackensack University Medical Center Urology
    • New York
      • Syracuse, New York, 미국, 13210
        • Associated Medical Professionals
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • Levine Cancer Institute, Carolinas HealthCare System
    • Ohio
      • Gahanna, Ohio, 미국, 43230
        • Central Ohio Urology Group
    • South Carolina
      • Myrtle Beach, South Carolina, 미국, 29572
        • Carolina Urologic Research Center
      • North Charleston, South Carolina, 미국, 29406
        • Low Country Urology Clinics
    • Tennessee
      • Nashville, Tennessee, 미국, 37209
        • Urology Associates
    • Texas
      • Austin, Texas, 미국, 78745
        • Urology Austin
      • San Antonio, Texas, 미국, 78229
        • Urology San Antonio Research
      • Barcelona, 스페인, 08025
        • Fund. Puigvert
      • Barcelona, 스페인, 08036
        • Hosp Clinic de Barcelona
      • Barcelona, 스페인, 08035
        • Hosp Univ Vall D Hebron
      • Córdoba, 스페인, 14004
        • Hosp Reina Sofia
      • Madrid, 스페인, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28046
        • Hosp. Univ. La Paz
      • Madrid, 스페인, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Valencia, 스페인, 46009
        • Instituto Valenciano de Oncologia
      • Haifa, 이스라엘, 3109601
        • Rambam Medical Center
      • Haifa, 이스라엘, 3436212
        • Carmel Medical Center
      • Petah Tikva, 이스라엘, 4941492
        • Rabin Medical Center
      • Tel Aviv, 이스라엘, 64239
        • Tel Aviv Sourasky Medical Center
      • Fukuoka, 일본, 810 8563
        • National Hospital Organization Kyushu Medical Center
      • Kofu, 일본, 400-8506
        • Yamanashi Prefectural Central Hospital
      • Osaka, 일본, 558-8558
        • Osaka General Medical Center
      • Toyama, 일본, 930 0194
        • Toyama University Hospital
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 1M9
        • Vancouver Prostate Centre Diamond Health Care Centre
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 2Y9
        • Nova Scotia Health Authority
    • Ontario
      • Hamilton, Ontario, 캐나다, L8N 4A6
        • St Josephs Healthcare Hamilton
      • Toronto, Ontario, 캐나다, M5G 2M9
        • Princess Margaret Cancer Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Parts 1-3:

  • Muscle-invasive or recurrent, non-muscle-invasive urothelial carcinoma of the bladder
  • For selected Cohorts: Activating tumor pan-fibroblast growth factor receptor (FGFR) mutation or fusion, as determined by local or central testing, approved by the sponsor prior to the start of study treatment. Local tissue-based results (if already existing) from next-generation sequencing (NGS) or polymerase chain reaction (PCR) tests performed in Clinical Laboratory Improvement Amendments (CLIA) -certified or equivalent laboratories, or results from commercially available PCR or NGS tests
  • Cohorts 1 and 2: Bacillus Calmette-Guérin (BCG) experienced, or participants with no BCG experience because BCG was not available as a treatment option in the participant's location within the previous 2 years and is currently unavailable. Participants who received an abbreviated course of BCG due to toxicity are still eligible
  • Cohort 1 only: Refuses or is not eligible for radical cystectomy (RC)
  • Cohorts 2 and 4: Willing and eligible for RC

Part 4:

  • Have histologically confirmed diagnosis of recurrent Intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC) Ta LG tumors
  • Must not have undergone tumor debulking or selective ablation of visible lesions; partial tumor biopsy to confirm diagnosis and provide tissue for biomarker testing is permitted as long as remaining tumor is at least 5 millimeter (mm) in size
  • Must submit tissue and urine for FGFR testing
  • Can have a prior or concurrent second malignancy which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment

Exclusion Criteria:

Parts 1-3:

  • Concurrent extra-vesical (that is, urethra, ureter, renal pelvis) transitional cell carcinoma of the urothelium
  • Prior treatment with an pan-fibroblast growth factor receptor (FGFR) inhibitor
  • Received pelvic radiotherapy <=6 months prior to the planned start of study treatment. If received pelvic radiotherapy greater than (>)6 months prior to the start of study treatment, there must be no cystoscopic evidence of radiation cystitis
  • Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe use of Erdafitinib intravesical delivery system
  • Indwelling urinary catheter. Intermittent catheterization is acceptable

Part 4:

  • Histologically confirmed diagnosis of T1 NMIBC, HR NMIBC (HG/G2 or HG/G3 or CIS) or MIBC, locally advanced, non-resectable, or metastatic urothelial carcinoma at any time prior to enrollment. Previous high grade (HG) disease is accepted as long as diagnosis date is greater than or equal to (>=5) years ago and there is documentation of low grade (LG) Ta thereafter
  • Known allergies, hypersensitivity, or intolerance to any study component or its excipients
  • Has a current diagnosis of newly diagnosed IR-NMIBC
  • Received an investigational treatment for bladder cancer after Transurethral Resection of the Bladder Tumor (TURBT) for the current NMIBC diagnosis or within 4 weeks or the agent/therapy washout period, whichever is longer, before the planned first dose of study treatment, or is currently enrolled in an investigational study
  • Evidence of current bladder perforation by cystoscopy or imaging

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part 1: Dose Escalation

Participants with recurrent, bacillus Calmette-Guerin (BCG)-experienced high risk papillary-only Non-Muscle-Invasive Bladder Cancer (NMIBC), refusing or ineligible for radical cystectomy or with recurrent, intermediate-risk NMIBC will receive Erdafitinib Intravesical Delivery System. The dose will be escalated to determine preliminary recommended phase 2 dose(s) (RP2D[s]) for Part 2.

Erdafitinib intravesical delivery system will be administered.

다른 이름들:
  • JNJ-42756493
실험적: Part 2: Dose Expansion

Participants in each of 5 disease-specific NMIBC or MIBC cohorts may be enrolled at one or more dose levels that have been determined to be safe in Part 1.

Erdafitinib intravesical delivery system will be administered.

다른 이름들:
  • JNJ-42756493
실험적: Part 3: RP2D Dose Expansion

Participants in 2 of the disease-specific NMIBC cohorts (cohorts 1 and 3) may be enrolled at RP2D to determine the safety, evaluate PK and preliminary clinical activity.

Erdafitinib intravesical delivery system will be administered.

다른 이름들:
  • JNJ-42756493
실험적: Part 4: Phase 2 Expansion

Participants with recurrent IR-NMIBC will be enrolled in this part to further evaluate the safety, efficacy, and PK of the selected RP2D.

Erdafitinib intravesical delivery system will be administered.

다른 이름들:
  • JNJ-42756493

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Parts 1 to 3: Number of Participants with Adverse Events (AEs)
기간: Up to approximately 7 years 4 months

An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Up to approximately 7 years 4 months
Parts 1 to 3: Number of Participants with AEs by Severity
기간: Up to approximately 7 years 4 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to approximately 7 years 4 months
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
기간: Up to 28 days

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 28 days
Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)
기간: Up to approximately 7 years 4 months

Overall CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy.

Up to approximately 7 years 4 months

2차 결과 측정

결과 측정
측정값 설명
기간
Parts 1 to 3: Plasma Concentration of Erdafitinib
기간: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks

Plasma concentration of Erdafitinib will be reported.

Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
Parts 1 to 3: Urine Concentration of Erdafitinib
기간: Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks

Urine concentration of Erdafitinib will be reported.

Cohorts 1, 3 and 5: up to 6 months; Cohort 2 and 4: up to 8 weeks
Parts 1 to 3: Cohorts 1 and 2: Recurrence-Free Survival (RFS)
기간: Up to approximately 7 years 4 months

RFS is defined as the time from start of treatment to the first detection of any new high-grade bladder cancer or upper tract urothelial carcinoma or positive urine cytology.

Up to approximately 7 years 4 months
Parts 1 to 3: Cohort 3 and 5: Complete Response (CR) Rate
기간: At 3 months

CR is defined as the absence of urothelial carcinoma by cystoscopy, confirmed pathologically at first assessment, and negative urine cytology.

At 3 months
Parts 1 to 3: Cohort 3 and 5: Duration of CR
기간: Up to approximately 7 years 4 months

Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.

Up to approximately 7 years 4 months
Parts 1 to 3: Cohort 4: Pathological Complete Response (pCR) Rate
기간: Up to 8 weeks

pCR rate is defined as percentage of participants with no pathologic evidence of intravesical disease (pT0) and no pathologic evidence of nodal involvement (pN0).

Up to 8 weeks
Parts 1 to 3: Cohort 4: No Pathologic Evidence of Intravesical Disease (pT0)
기간: Up to 8 weeks

pT0 rate is defined as percentage of participants with no Pathologic Evidence of Intravesical Disease.

Up to 8 weeks
Parts 1 to 3: Cohort 4: Rate of downstaging to Less than (<) pT2
기간: Up to 8 weeks

Rate of downstaging to <pT2 is defined as percentage of participants with pT stage <2.

Up to 8 weeks
Part 4: Duration of CR (DoCR) in Participants with IR-NMIBC
기간: Up to approximately 7 years 4 months

Duration of CR is defined as the time from first documentation of CR until the date of documented recurrence or progression, or death, whichever comes first.

Up to approximately 7 years 4 months
Part 4: Complete Response (CR) at 3 Months in Participants with IR-NMIBC
기간: At Month 3

CR is defined as the negative cystoscopy or positive cystoscopy with centrally reviewed biopsy negative for malignancy at the first disease evaluation.

At Month 3
Part 4: Transurethral Resection of the Bladder Tumor (TURBT)-Free Survival in Participants With IR-NMIBC
기간: Up to approximately 7 years 4 months

Participants with TURBT-free survival will be reported.

Up to approximately 7 years 4 months
Part 4: Number of Participants with Treatment-Emergent Adverse Event (TEAEs) by Severity
기간: Up to approximately 7 years 4 months

TEAEs are AEs with onset during the intervention phase or that are a consequence of a pre-existing condition that has worsened since baseline. Severity was assessed using National cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity grades ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to approximately 7 years 4 months
Part 4: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) Score
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the health-related quality of life (HRQoL) of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status / quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.

At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Change from Baseline in European Organization for the Research and Treatment of Cancer Non-Muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC 24) Score
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-C30 Scores
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

The EORTC QLQ-C30, is a self-administered, 30-item questionnaire measuring the HRQoL of participants with cancer. EORTC QLQ-C30 includes 5 functional scales, 3 symptom scales, a global health status/quality of life scale, and 6 single items. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much." Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent." Higher scores indicate greater functioning, better global health status, and more severe symptoms.

At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)
Part 4: Percentage of Participants With Clinically Meaningful Change From Baseline in EORTC-QLQ-NMIBC24 Scores
기간: At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity.

At baseline (Week 0), Weeks 12, 24, 36, 48, and at completion or discontinuation of study treatment (up to approximately 7 years 4 months)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 4월 11일

기본 완료 (추정된)

2028년 3월 30일

연구 완료 (추정된)

2029년 7월 24일

연구 등록 날짜

최초 제출

2022년 3월 30일

QC 기준을 충족하는 최초 제출

2022년 3월 30일

처음 게시됨 (실제)

2022년 4월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다